KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Divestments (2020 - 2025)

Teva Pharmaceutical Industries' Divestments history spans 6 years, with the latest figure at $8.0 million for Q3 2025.

  • For the quarter ending Q3 2025, Divestments fell 78.95% year-over-year to $8.0 million, compared with a TTM value of $34.0 million through Dec 2025, down 20.93%, and an annual FY2025 reading of $34.0 million, down 20.93% over the prior year.
  • Divestments for Q3 2025 was $8.0 million at Teva Pharmaceutical Industries, down from $9.0 million in the prior quarter.
  • The five-year high for Divestments was $138.0 million in Q1 2021, with the low at $1.0 million in Q2 2024.
  • Average Divestments over 5 years is $30.8 million, with a median of $17.0 million recorded in 2025.
  • Year-over-year, Divestments soared 2200.0% in 2021 and then crashed 98.21% in 2024.
  • Tracing TEVA's Divestments over 5 years: stood at $42.0 million in 2021, then crashed by 45.24% to $23.0 million in 2022, then tumbled by 56.52% to $10.0 million in 2023, then plummeted by 60.0% to $4.0 million in 2024, then skyrocketed by 100.0% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Divestments are $8.0 million (Q3 2025), $9.0 million (Q2 2025), and $17.0 million (Q1 2025).